The Association Between COVID-19 Vaccination and Health-Related Quality of Life and Work Productivity: A Systematic Literature Review
Author(s)
Carolina Casañas i Comabella, PhD1, Tianyan Hu, MSc2, Carlos Fernando Mendoza, MSc2, Salima Punja, PhD3, Heather Burnett, MSc3, Hannah R. Volkman, PhD2, Santiago Lopez, MSc2, Rachel M. Black, PharmD2, Jingyan Yang, DrPH2, Manuela Di Fusco, MSc2.
1Associate Director, Evidera, Oxford, United Kingdom, 2Pfizer Inc, New York, NY, USA, 3Evidera, St-Laurent, QC, Canada.
1Associate Director, Evidera, Oxford, United Kingdom, 2Pfizer Inc, New York, NY, USA, 3Evidera, St-Laurent, QC, Canada.
Presentation Documents
OBJECTIVES: The value of vaccination from a health policy perspective expands beyond clinical efficacy/effectiveness and safety. This study characterized the association between COVID-19 vaccination and post-COVID health-related quality of life (HRQoL) and work productivity/impairment.
METHODS: A systematic literature review was conducted in Embase and MEDLINE to capture studies published between 1/1/2021-10/8/2024. Studies were included if they compared post-COVID HRQoL and/or work productivity/impairment in individuals of any age who received a COVID-19 vaccine (primary series or booster) versus another vaccine or no vaccine.
RESULTS: Five studies (9 publications) were included: n=2 reporting HRQoL and n=4 work productivity. Studies were conducted in adults in US (n=2), Greece (n=2), and Israel (n=1), and included healthcare workers (HCW) (n=2 studies), acute outpatient infections (n=2), patients hospitalized with COVID-19 (n=1), and patients with long-COVID (n=1). All studies assessed BNT162b2 (n=3 primary series only; n= 3 booster only; n=2 both primary series and booster). No other COVID-19 vaccines were studied. Two studies observed better EQ-5D utility index (UI) in individuals who received boosters (UI=0.83) versus unvaccinated (UI=0.76), driven by significantly lower symptom burden (p=0.002). Individuals with long-COVID who received a booster reported significantly higher EQ-5D UI versus unvaccinated (0.922 vs 0.731, p=0.014). Significantly lower presenteeism, work impairment, and productivity loss were reported in BNT162b2 versus unvaccinated. Long-COVID patients who had received a booster presented lower activity impairment versus unvaccinated. Vaccinated HCWs had significantly fewer absenteeism episodes versus unvaccinated (p<0.001) and significantly fewer days off work versus partially vaccinated (p<0.001).
CONCLUSIONS: Data on the association between COVID-19 vaccination and post-COVID HRQoL and work productivity are relatively scant and limited to BNT162b2. Studies consistently show that individuals vaccinated with BNT162b2 present better post-COVID HRQoL and work productivity than those unvaccinated or partially vaccinated based on local recommendations. Further research is needed for future adapted COVID-19 vaccines.
METHODS: A systematic literature review was conducted in Embase and MEDLINE to capture studies published between 1/1/2021-10/8/2024. Studies were included if they compared post-COVID HRQoL and/or work productivity/impairment in individuals of any age who received a COVID-19 vaccine (primary series or booster) versus another vaccine or no vaccine.
RESULTS: Five studies (9 publications) were included: n=2 reporting HRQoL and n=4 work productivity. Studies were conducted in adults in US (n=2), Greece (n=2), and Israel (n=1), and included healthcare workers (HCW) (n=2 studies), acute outpatient infections (n=2), patients hospitalized with COVID-19 (n=1), and patients with long-COVID (n=1). All studies assessed BNT162b2 (n=3 primary series only; n= 3 booster only; n=2 both primary series and booster). No other COVID-19 vaccines were studied. Two studies observed better EQ-5D utility index (UI) in individuals who received boosters (UI=0.83) versus unvaccinated (UI=0.76), driven by significantly lower symptom burden (p=0.002). Individuals with long-COVID who received a booster reported significantly higher EQ-5D UI versus unvaccinated (0.922 vs 0.731, p=0.014). Significantly lower presenteeism, work impairment, and productivity loss were reported in BNT162b2 versus unvaccinated. Long-COVID patients who had received a booster presented lower activity impairment versus unvaccinated. Vaccinated HCWs had significantly fewer absenteeism episodes versus unvaccinated (p<0.001) and significantly fewer days off work versus partially vaccinated (p<0.001).
CONCLUSIONS: Data on the association between COVID-19 vaccination and post-COVID HRQoL and work productivity are relatively scant and limited to BNT162b2. Studies consistently show that individuals vaccinated with BNT162b2 present better post-COVID HRQoL and work productivity than those unvaccinated or partially vaccinated based on local recommendations. Further research is needed for future adapted COVID-19 vaccines.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
PCR46
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, STA: Vaccines